OR WAIT null SECS
Aesica Pharmaceuticals has built a new high-capacity manufacturing facility specifically for the production of solid dose medications used in the treatment of type II diabetes at its UK site in Queenborough, Kent.
Aesica Pharmaceuticals, a CDMO specializing in formulated products and APIs, announced that it has built a new high-capacity manufacturing facility at its UK site in Queenborough, Kent. The company invested £30 million towards the 10,000 m2 expansion of the new facility, which has been constructed specifically for the production of solid dose medications used in the treatment of type II diabetes.
The facility, which will commence commercial production in November 2013, contains highly technical and specialist equipment including spray granulators, coaters, tablet presses, a delumper, blender and a sieve system.
Her Majesty’s Lord-Lieutenant of Kent, Viscount De L’Isle attended the opening ceremony of the new facility in recognition of Aesica’s contribution to the economy through the creation of new jobs following its commercial expansion. Aesica will recruit 55 technicians who will be trained on site. The design of the facility will allow the current capacity to be more than doubled in the future, which would open up another 50 jobs.